Compare Centrus Energy Corp (LEU) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Centrus Energy (LEU) trades at $134.28, down 0.76% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows elevated valuation metrics with a P/E of 63.47 and P/S of 5.64, while profitability metrics remain solid with a 10.23% net income margin. Recent news highlights Centrus' strategic positioning as the only US-licensed producer of high-assay low-enriched uranium (HALEU), with multiple new supply contracts announced in September 2026.

The investment case hinges on execution of nuclear fuel contracts amid growing demand, but faces risks from high valuation and operational challenges. Analyst consensus remains positive with a $218.10 price target, though technical indicators suggest near-term pressure. The company's unique position in the nuclear supply chain offers growth potential, but requires careful monitoring of cash flow trends and contract execution.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.